Par Drugs And Chemicals Limited · NSE:PAR
Par Drugs And Chemicals — Investor Presentation (November 2020)
28 slides from Par Drugs And Chemicals's investor presentation, Nov 5, 2020
Slide 1: Exchange covering letter for Investors Presentation
PAR/CS/NSE/2020-21/41 To, Date: 05/11/2020 The Manager Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai- 400 051 Maharashtra Symbol - PAR (NSE Emerge), ISIN: INE04LG01015 Subject: Investors Presentation Ref.: Regulati
Slide 2: Investor Presentation | November 2020
Investor Presentation| November 2020
Slide 3: Executive Summary
2 Executive Summary Overview • Incorporated in 1999, Par Drugs and Chemicals Ltd. (PDCL) is engaged in the development and manufacture of Active Pharma Ingredients (“APIs”) and Fine Chemicals for the domestic market as well as for exports to international markets. • The company currently produces th
Slide 4: Company Overview
Company Overview
Slide 5: About the Company
4 About the Company Operational Revenues (INR Mn) • Promoted by Mr. Falgun Savani and Mr. Jignesh Savini, Par Drugs and Chemicals Ltd. (PDCL) was founded in 1982 and is engaged in the development and 194 199 164 manufacturing of APIs. 134 • The Company today manufactures more than 28 different produ
Slide 6: Board of Directors
5 Board of Directors Falgun Vallabhbhai Savani Pravin Manjibhai Bhayani Managing Director Independent Director • Holds Bachelor’s degree in Pharmacy from B. K. Modi Government Pharmacy College, Rajkot affiliated with Saurashtra University. Kajal Chintanbhai Vaghani • Has 18 years of experience in th
Slide 7: Geographical Presence
6 Geographical Presence Canada United Kingdom Germany Iran Syria Japan Jordan China PRP South Korea India Hong Kong UAE Bangladesh Thailand Sri Lanka Indonesia Colombia 40+ 13+ Manufacturing Facility Bhavnagar, Gujarat having a capacity of 8,300 MTPA. Agents Globally Dealers in India
Slide 8: Key Milestones
7 Key Milestones Mr. V. J. Savani established in the year 1982 in the name of Par Inorganics, later Par Drugs and Chemicals was incorporated in the year 1999. • Established 2nd manufacturing facility in Asia's Received GMP • Had addition of one • Conversion from biggest chemicals Certification from
Slide 9: Research & Development
8 Research & Development • Company’s focus is on developing non-infringing processes and achieving process improvements and production cost efficiencies. • The main focus will be to expand the ability to penetrate different applications of current molecules with modified physical and chemical struct
Slide 10: Manufacturing Facility
9 Manufacturing Facility Manufacturing Facility - Chitra, Bhavnagar, Gujarat There are three Manufacturing Blocks are for different products having a capacity of 8,300 MTPA. Unit 1 – APIs Unit 2 - Magnesium Hydroxide Unit 3 - Fine Chemicals
Slide 11: Manufacturing Process
10 Manufacturing Process Procurement of Raw Quality Control and Reaction Filtration Drying Packaging Material Sampling Procurement of Chemical reaction After the reaction, Excess water from The sampling is The material is sent magnesium takes place in a the slurry has to be the product is done for t
Slide 12: Key Strengths
11 Key Strengths Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 18 APIs and 10 Fine Chemicals which are marketed domestically and exported. Global Presence: The Company is operating both in domestic and e
Slide 13: Business Overview
Business Overview
Slide 14: Business Overview
13 Business Overview The company is one of the largest manufacturer in Magnesium Hydroxide, Sucralfate and Magnesium Trisilate in India. API (65%) Fine Chemicals (35%) Magnesium Hydroxide Magnesium Oxide USP Precipitated Silica Sodium Aluminium Silicate Sucralfate Almagate BP Amorphous Aluminium Hyd
Slide 15: Business Verticals
14 Business Verticals API • PDCL currently produces the entire range of Antacid Molecules available in the market. • Antacids are medication that neutralizes stomach acid to cut down on heartburn, sour stomach, acid indigestion, and stomach upset, symptoms of Gastroesophageal Reflux Disease (GERD al
Slide 16: APIs and their Applications
15 APIs and their Applications Magnesium Hydroxide Magnesium Aluminosilicate-USP Hydrotalcite • Widely used as an Antacid in many Formulations • Used as an Antacid Raw material in a specific • Used as an API in Antacid Formulation. helping reduce stomach acid antacid Formulation • Also used as inter
Slide 17: Fine Chemicals and their Applications
16 Fine Chemicals and their Applications Fine chemicals are chemical substances prepared to a very high degree of purity. They can be used in different industries. These chemicals are used for special applications by manufacturing firms that make the following products: Pharmaceuticals, paints, petr
Slide 18: Future Strategy
17 Future Strategy Expand the product portfolio: Seek to leverage the R&D capabilities to expand PDCL’s Product Portfolio and thus penetrate the different segments of application and value added products. This will ultimately increase the profitability by value addition. Exploring new geographical a
Slide 19: Industrial Overview
Industrial Overview
Slide 20: API Industry
19 API Industry Global API Market Size Global Anatcid Market Size (USD Bn) (USD Bn) • More than 30% of the APIs manufactured in India are exported to countries such as US, UK, CAGR 6.5% CAGR 3.9% Japan, etc. The total production market of API in India was valued at approximately USD 11 Bn in FY16. T
Slide 21: Fine Chemical Industry
20 Fine Chemical Industry • The global Fine Chemicals market is valued at USD 1,55,550 Mn in 2018 and is expected to reach USD 2,19,490 Mn by the end of 2024, growing at a CAGR of 7.1% between 2019 and 2024. • North America and Europe is the industry’s leading region. In 2018, the revenue of Fine Ch
Slide 22: Financial Overview
Financial Overview
Slide 23: Income Statement (IND-AS)
22 Income Statement (IND-AS) Income Statement (INR Mn) FY18 FY19 FY20 H1-FY21 Income from Operations 424 463 558 283 Total Expenses 344 381 464 205 EBITDA 80 82 94 78 EBITDA Margin 18.87% 17.71% 16.85% 27.56% Finance Cost 23 20 8 3 Depreciation 31 30 27 15 Other Income - 1 1 1 PBT 26 33 60 61 Tax 11
Slide 24: Balance Sheet (IND-AS)
23 Balance Sheet (IND-AS) EQUITIES & LIABILITIES (INR Mn) FY19 FY20 H1-FY21 ASSETS (INR Mn) FY19 FY20 H1-FY21 Shareholder Funds 290 406 457 Non Current Assets 371 359 350 (A) Equity Share Capital 45 61 61 (A) Fixed Assets (B) Reserves & Surplus 245 345 396 (i) Tangible Assets 363 344 330 (ii) Capita
Slide 25: Financial Highlights
24 Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 558 8.60% 463 18.87% 424 17.71% 5.40% 16.85% 3.54% 80 82 94 15 25 48 FY18 FY19 FY20 FY18 FY19 FY20 FY18 FY19 FY20 RoCE & RoE Debt to Equity Ratio Net Worth (INR Mn) RoE (%) RoCE (
Slide 26: Market Data
25 Market Data Price Data (30th September, 2020) INR Shareholding Pattern as on 30th September, 2020 Face Value 10.0 Market Price 49.4 Public High/Low 52.8/26.2 27% Market Cap (Mn) 303.9 Promoters 73% Equity Shares Outstanding (Mn) 6.2 1 Year Avg Trading Volume (‘000) 8.6
Slide 27: Disclaimer
26 Disclaimer Par Drugs & Chemicals Ltd Disclaimer: The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connect
Slide 28: Thank You
Thank You
Par Drugs and Chemicals — Investor Presentation (November 2020) on 6ix